These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Turpie AG; Mason JA Expert Opin Pharmacother; 2002 May; 3(5):575-98. PubMed ID: 11996636 [TBL] [Abstract][Full Text] [Related]
6. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics. Agnelli G; Sonaglia F Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128 [TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin for the treatment of venous thromboembolism. Hirsh J Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S336-42. PubMed ID: 9628447 [TBL] [Abstract][Full Text] [Related]
8. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Dunn CJ; Sorkin EM Drugs; 1996 Aug; 52(2):276-305. PubMed ID: 8841743 [TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Martineau P; Tawil N Ann Pharmacother; 1998 May; 32(5):588-98, 601. PubMed ID: 9606481 [TBL] [Abstract][Full Text] [Related]
10. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569 [TBL] [Abstract][Full Text] [Related]
11. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update. Cohen M Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045 [TBL] [Abstract][Full Text] [Related]
12. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Agnelli G; Iorio A; Renga C; Boschetti E; Nenci GG; Ofosu FA; Hirsh J Circulation; 1995 Nov; 92(10):2819-24. PubMed ID: 7586247 [TBL] [Abstract][Full Text] [Related]
13. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis]. Shen Y; Kang J Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122 [TBL] [Abstract][Full Text] [Related]
14. Recent clinical trials in the treatment of venous thromboembolism and unstable angina with low molecular weight heparins. Hirsh J Curr Opin Hematol; 1998 Sep; 5(5):360-5. PubMed ID: 9776217 [TBL] [Abstract][Full Text] [Related]
15. Safety profile of different low-molecular weight heparins used at therapeutic dose. Gouin-Thibault I; Pautas E; Siguret V Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242 [TBL] [Abstract][Full Text] [Related]
17. The use of low-molecular-weight heparins in cardiovascular disease. Verhaeghe R Acta Cardiol; 1998; 53(1):15-21. PubMed ID: 9638965 [TBL] [Abstract][Full Text] [Related]
18. Low-molecular weight heparins in venous and arterial thrombotic disease. Bijsterveld NR; Hettiarachchi R; Peters R; Prins MH; Levi M; Büller HR Thromb Haemost; 1999 Sep; 82 Suppl 1():139-47. PubMed ID: 10695506 [TBL] [Abstract][Full Text] [Related]
19. [Therapeutic indications for acute venous thromboembolism. Current status and future perspectives]. Prandoni P; Simioni P; Pagnan A Minerva Cardioangiol; 2003 Aug; 51(4):361-71. PubMed ID: 12900718 [TBL] [Abstract][Full Text] [Related]
20. New perspectives for treatment of pulmonary embolism. Simonneau G Haemostasis; 1998; 28 Suppl 3():95-9. PubMed ID: 10069768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]